Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'Autism Risperidone Behavioral-symptoms Hyperactivity Irritability Safety'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial / Gahan PANDINA in Journal of Autism and Developmental Disorders, 37-2 (February 2007)
[article]
Titre : Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial Type de document : Texte imprimé et/ou numérique Auteurs : Gahan PANDINA, Auteur ; Cynthia A. BOSSIE, Auteur ; Eriene YOUSSEF, Auteur ; Young ZHU, Auteur ; Fiona DUNBAR, Auteur Année de publication : 2007 Article en page(s) : p.367-373 Langues : Anglais (eng) Mots-clés : Autism Risperidone Behavioral-symptoms Hyperactivity Irritability Safety Index. décimale : PER Périodiques Résumé : Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n = 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), P < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism. En ligne : http://dx.doi.org/10.1007/s10803-006-0234-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=641
in Journal of Autism and Developmental Disorders > 37-2 (February 2007) . - p.367-373[article] Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial [Texte imprimé et/ou numérique] / Gahan PANDINA, Auteur ; Cynthia A. BOSSIE, Auteur ; Eriene YOUSSEF, Auteur ; Young ZHU, Auteur ; Fiona DUNBAR, Auteur . - 2007 . - p.367-373.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 37-2 (February 2007) . - p.367-373
Mots-clés : Autism Risperidone Behavioral-symptoms Hyperactivity Irritability Safety Index. décimale : PER Périodiques Résumé : Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n = 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), P < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism. En ligne : http://dx.doi.org/10.1007/s10803-006-0234-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=641